Evidence map›Paper›PMID 39145784›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Development of [

Jianhao Chen, Yizhen Pang, Xiyi Liao, Yangfan Zhou, Qicong Luo, Hua Wu, Changjing Zuo, Jingjing Zhang, Qin Lin, Xiaoyuan Chen and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jianhao Chen *Department of Nuclear Medicine and Minnan PET Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Yizhen Pang *Department of Nuclear Medicine and Minnan PET Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Xiyi Liao *Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Yangfan ZhouDepartment of Nuclear Medicine and Minnan PET Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Qicong LuoLaboratory of Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Hua WuDepartment of Nuclear Medicine and Minnan PET Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Changjing ZuoDepartment of Nuclear Medicine, The First Affiliated Hospital of Naval Military Medical University (Shanghai Changhai Hospital), Shanghai, China.
Jingjing ZhangDepartments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore, Singapore.
Qin LinDepartment of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Xiaoyuan ChenDepartments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore, Singapore. chen.shawn@nus.edu.sg.
Liang ZhaoDepartment of Nuclear Medicine and Minnan PET Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. wzhaoliang01@163.com.
Haojun ChenDepartment of Nuclear Medicine and Minnan PET Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. leochen0821@foxmail.com.ORCID 0000-0002-9101-8884

Funding

Fujian Natural Science Foundation for Distinguished Yong Scholars 2022D005Key Scientific Research Program for Yong Scholars in Fujian 2021ZQNZD016National Medical Research Council MOH-001388-00, CG21APR1005National Natural Science Foundation of China 82071961National Research Foundation NRF-000352-00Singapore Ministry of Education MOE-000387-00the National University of Singapore NUHSRO/2020/133/Startup/08, NUHSRO/2023/008/NUSMed/TCE/LOA, NUHSRO/2021/034/TRP/09/Nanomedicine
6 · The paper itself

Abstract

purposeSomatostatin Receptor 2 (SSTR2)-targeted radiopharmaceutical [

methodsWe assessed binding characteristics of LNC1010 in vitro using C666-1 NPC cells and in-vivo pharmacokinetics of [

resultsLNC1010 exhibited strong uptake and specific affinity for SSTR2 in C666-1 NPC cells. PET and SPECT imaging demonstrated higher uptake and longer tumour retention of [

conclusion[

Indexed as

Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsReceptors, SomatostatinAnimalsCell Line, TumorFemaleHumansLutetiumMaleMiceOctreotideRadioisotopesRadiopharmaceuticalsTissue DistributionLutetiumLutetium-177OctreotideRadioisotopesRadiopharmaceuticalsReceptors, SomatostatinEvans blueLNC1010Nasopharyngeal carcinomaPeptide receptor radionuclide therapySomatostatin receptor 2

Identifiers

PMID39145784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.